Last reviewed · How we verify
BDP/salbutamol HFA pMDI
BDP/salbutamol is a combination inhaler that reduces airway inflammation via corticosteroid action while providing rapid bronchodilation through beta-2 agonist stimulation.
BDP/salbutamol is a combination inhaler that reduces airway inflammation via corticosteroid action while providing rapid bronchodilation through beta-2 agonist stimulation. Used for Asthma maintenance and reliever therapy, Chronic obstructive pulmonary disease (COPD) with reversible airflow obstruction.
At a glance
| Generic name | BDP/salbutamol HFA pMDI |
|---|---|
| Sponsor | Chiesi Farmaceutici S.p.A. |
| Drug class | Combination inhaled corticosteroid and short-acting beta-2 agonist (ICS/SABA) |
| Target | Glucocorticoid receptor (BDP); Beta-2 adrenergic receptor (salbutamol) |
| Modality | Small molecule |
| Therapeutic area | Respiratory / Pulmonology |
| Phase | Phase 3 |
Mechanism of action
Beclomethasone dipropionate (BDP) is an inhaled corticosteroid that suppresses airway inflammation by binding glucocorticoid receptors, reducing mucus production and airway edema. Salbutamol (albuterol) is a short-acting beta-2 adrenergic agonist that rapidly relaxes bronchial smooth muscle, providing quick relief of bronchoconstriction. The combination allows both maintenance anti-inflammatory control and acute symptom relief in a single inhaler.
Approved indications
- Asthma maintenance and reliever therapy
- Chronic obstructive pulmonary disease (COPD) with reversible airflow obstruction
Common side effects
- Tremor
- Headache
- Palpitations
- Oral candidiasis
- Throat irritation
- Nervousness
Key clinical trials
- Efficacy and Tolerability of Beclomethasone Plus Salbutamol in HFA pMDI Fixed Combination vs Beclomethasone Plus Salbutamol in CFC pMDI Fixed Combination in a 12-week Treatment Period of Adult Patients With Uncontrolled Asthma (PHASE3)
- Bronchodilator Effect of CHF1535 pMDI Versus Free Combination of Beclometasone Plus Formoterol pMDI in Asthmatic Children (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BDP/salbutamol HFA pMDI CI brief — competitive landscape report
- BDP/salbutamol HFA pMDI updates RSS · CI watch RSS
- Chiesi Farmaceutici S.p.A. portfolio CI